Scholar Rock Holding Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi, everyone. I think it's time. My name is Phoebe Tan. I'm a Jefferies equity research analyst, and today I have the pleasure of hosting Scholar Rock, David Hallal, CEO. I'm going to pass it over to you for some intro remarks first.
Great. Thanks, Phoebe. I can accurately comment that it is literally standing room only here in the fireside chat room. It's great to have everybody here, and it's an extraordinary moment in time for Scholar Rock. As many of you know, we just received FDA approval for the first and only muscle-targeted therapy for the treatment of children and adults living with SMA in the U.S. That came just at the tail end of quarter three, here in the middle of September. At long last, the U.S. launch is underway. We are gratified that after 30 years of following the discovery of myostatin at Johns Hopkins, and after 20 years of failed clinical development across a wide range of biopharma companies, Scholar Rock was the first and only company to take a myostatin inhibitor all the way through clinical development and now to regulatory approval.
I know Phoebe will have a chance to talk about the dynamics that we are observing early in the launch in the U.S., but I would also note that our ambition is to reach the 35,000 to 40,000 patients globally that are receiving at least one SMN-targeted therapy. At Scholar Rock, our ambition is to operate in up to 50 countries around the world. Importantly, we are back on file with the European Medicines Agency. Our MAA has been validated, and we expect a CHMP opinion in the first half of 2027. I would also note, importantly, that following that opinion, we would expect to launch first in Germany later in 2027, and then work with each individual European country for pricing and reimbursement agreements.
Importantly, we also had just shared last week during our earnings call, as Phoebe knows quite well, that we also submitted our JNDA to the PMDA in Japan 2 months earlier than our guidance. The JNDA was accepted under priority review. PMDA usually targets a nine-month review for such applications, and we are super excited to have the opportunity next year to start serving children and adults living with SMA in both the important region of Europe and the important country of Japan. We are just the first of two products under a new program in Japan where we were allowed to file for a full approval without local Japanese clinical trial data. This has expedited our process quite a bit.
Look forward to discussing our ambitions and serving the global SMA community here this afternoon, as well as any pipeline initiatives that Phoebe may be interested in raising as well.
Perfect. Thank you for that. Just to begin with the U.S. launch, on your Q3 call, you mentioned steady new patient adds week over week. Is there any color or directional commentary that we can get there?
Yeah. We're super excited with the first six, eight weeks of observation since the FDA approval. One of the things that we wanted to share last week on our call, as Phoebe knows, is that we were very encouraged by both the strong volume of demand coming into our patient assistance program known as Scholar Rock Supports, and we're also very encouraged by the breadth of both prescribers and patients with SMA coming into the Scholar Rock Supports program. Essentially, you enter Scholar Rock Supports as an intent to treat by both the physician and the patient. Those are our patient enrollment forms, patient start forms, if you will.
As evidence of the volume that came in really just in the first six weeks since approval through the end of October, as we noted on the call, we had more new start forms coming in for ISEMBYLD treatment-naive patients, so patients that would be new to the product, than those that were receiving ISEMBYLD non-commercially through either our early access program or our long-term open-label extension trial from our phase II, phase III trials. That actually gives folks a flavor of just how much demand we have been able to see in just the first six weeks. We also noted a couple of key metrics related to that demand.
First and foremost, there's a top 140 SMA treatment centers in the U.S., and in just the first six weeks since approval, more than a third of those centers had started to submit enrollment forms into Scholar Rock Supports. Really strong evidence of an intent to treat. Yet, as Keith, our Chief Operating Officer, and I would say, the air is not thin with those more than one-third of centers. We will go much deeper into those centers, but nevertheless, we have initial enrollment forms from them. We're also encouraged that over time, we'll continue to keep you updated because we think we'll go very wide across those top 140 centers over time. The reason for that is, as I've noted, in the 2026 Cure SMA survey of patients living with SMA, 93% reported that muscle strength was a high unmet need that they have.
ISEMBYLD is the first and only muscle-targeted therapy now approved for SMA. This was by far the number one need requested by the patient community. On top of that, three-quarters of neurologists are now reporting that they believe the future of treatment of patients living with SMA is an approach that targets both the motor neuron and the muscle. Of course, for the last 10 years, they've had SMN-targeted therapies to use, like SPINRAZA, EVRYSDI, ZOLGENSMA, and now they have the first and only muscle-targeted therapy. So they see a combination approach as really being the future of treatment. So we really like what we've seen from the top 140 centers. We've also seen a substantial number of enrollment forms from doctors who are residing outside of those top 140 centers.
Maybe just a few of the dynamics from the patients that we saw coming in. Importantly, our U.S. label is indicated for all patients living with SMA, two years of age and older, provided that they are receiving an ongoing SMN2-targeted treatment, so EVRYSDI, SPINRAZA, or HD SPINRAZA. What we've seen so far in these first six weeks is, while there's more children enrolled in the program than adults, we see a substantial proportion of those enrollees being adults. We see pretty representative background therapy, like what you would expect with the prescribing patterns for EVRYSDI, SPINRAZA, HD SPINRAZA, and even some patients who received ZOLGENSMA and then subsequently went on to receive an SMN2-targeted therapy. So we see a nice blend there. We also are not necessarily seeing any one type of patient.
That is, we're seeing all types of disease trajectories, patients who have improving motor function, those whose motor function has plateaued, and some patients whose motor function has declined. So it is that balance and lack of a singular pattern which is giving us great confidence early on in this launch. Finally, what I would like to comment on, which we think is important, is we see geographically a lot of balance across the U.S. for where the demand is coming from. Quite important. Lastly, we haven't seen any peaks and valleys of demand. Really since approval, week on week, as Phoebe Tan was mentioning in the question, we see a consistent number of new patients enrolling in Scholar Rock Supports week on week.
Again, as evidence to our conviction that wherever the 6,600 patients are that are estimated to be receiving either SPINRAZA and EVRYSDI in the U.S., we want to be able to serve them. We think in time, we are going to be able to serve a very high proportion of those patients.
Perfect. Looking forward to your future disclosures, should we expect similar disclosures in terms of patient dynamics, as what you said in the Q3 call, or when can we expect to hear about new patient adds?
Yeah. It is a great question. Again, we are thrilled with both the volume that we are seeing coming into the system as well as the breadth and the diversity. One of the things we did note is that while we have had this consistent steady demand, from an access perspective, we see very early signs of positive reinforcement for patients living with SMA who want to access ISEMBYLD therapy. Keith noted on the call last week that two of the top payers in the United States, Anthem and Centene, already had published medical policies covering ISEMBYLD per FDA label. Really no restrictions that narrow the patient opportunity beyond that of the broad label that we have. I think that one of the things we would like to provide is how much wider are we going across the top 140 treatment centers.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
